Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Regulatory update – GSK announces regulatory submission for albiglutide in Europe
GSK today announced the submission of a MAA for albiglutide, with the proprietary name EPERZAN, to the European Medicines Agency (EMA).
-
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
ViiV present 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
-
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
Agreement brings the number of voluntary licences granted by ViiV Healthcare to 14.
-
GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD
GSK & THRX announced NDA for LAMA/LABA combination medicine, UMEC/VI, for patients with COPD has been accepted by the FDA.
-
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
ViiV announced that the FDA has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection.
-
Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
GSK announced submission of a Marketing Authorisation Application to EMA for MEK with BRAF for the treatment of adult patients with melanoma
-
Results announcement for the fourth quarter 2012
GSK delivers 2012 core EPS of 112.7p and returns £6.3bn to shareholders
-
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent
GSK announced it has successfully increased its publicly-listed Consumer Healthcare subsidiary in India, from 43.2% to 72.5%
-
GSK announces support for AllTrials campaign for clinical data transparency
Campaign calls for full disclosure of clinical trial results and clinical study reports to help drive scientific understanding.
-
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery
GSK today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib.
-
GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)
Responding to an article in The Guardian legal proceedings related to our type 2 diabetes medicine Avandia (rosiglitazone),
-
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
GSK & Biological E. announced an agreement for development of a paediatric vaccine to help protect children in India from polio
-
GSK appoints Hans Wijers to its Board as a Non-Executive Director
GSK announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013.
-
GSK signs up to UK Government’s Public Health Responsibility Deal
Pledge to reduce the sugar and calorie content of Lucozade Energy and Ribena products.
-
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
GSK announced a regulatory submission to the FDA for albiglutide, an investigational treatment for adult patients with type 2 diabetes.
-
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
GSK & THRX announced submission of regulatory application in the EU for the LAMA/LABA combination medicine for patients with COPD
-
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
GSK & THRX announced submission of regulatory application in US for LAMA/LABA combination medicine, UMEC/VI, for patients with COPD.
-
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
GSK announced ,FDA has approved FLUARIX QUADRIVALENT Influenza Vaccine for the immunisation of patients to help prevent seasonal influenza
-
Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines
GSK announced results from five Phase III studies investigating two candidate quadrivalent influenza vaccines. presented in Spain & US.
-
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
GSK CEO Sir Andrew Witty will outline new steps to build on progress resulting from open innovation approach to R&D.